Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Common Equity (2016 - 2025)

Regenxbio (RGNX) has 12 years of Common Equity data on record, last reported at $102.7 million in Q4 2025.

  • For Q4 2025, Common Equity fell 60.43% year-over-year to $102.7 million; the TTM value through Dec 2025 reached $102.7 million, down 60.43%, while the annual FY2025 figure was $102.7 million, 60.43% down from the prior year.
  • Common Equity reached $102.7 million in Q4 2025 per RGNX's latest filing, down from $161.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $764.3 million in Q4 2021 and bottomed at $102.7 million in Q4 2025.
  • Average Common Equity over 5 years is $414.3 million, with a median of $398.3 million recorded in 2023.
  • Peak YoY movement for Common Equity: soared 102.33% in 2021, then crashed 60.43% in 2025.
  • A 5-year view of Common Equity shows it stood at $764.3 million in 2021, then plummeted by 32.46% to $516.2 million in 2022, then plummeted by 39.61% to $311.7 million in 2023, then fell by 16.71% to $259.7 million in 2024, then plummeted by 60.43% to $102.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $102.7 million in Q4 2025, $161.5 million in Q3 2025, and $213.7 million in Q2 2025.